On May 13, 2026, MIRA Pharmaceuticals, Inc. reported the publication of a study showing that their drug candidate SKNY-1 reduced body weight by approximately 30% in a preclinical model, alongside improvements in cholesterol levels and behavioral effects related to obesity and nicotine addiction.